Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags [Seeking Alpha]
Armata Pharmaceuticals, Inc. (ARMP)
Company Research
Source: Seeking Alpha
AP-SA02, combined with standard-of-care antibiotics, showed superior clinical response rates and hospital metrics versus placebo. ARMP faces significant funding challenges, with only $14.8m in cash, $140m in liabilities, and dependence on majority holder Innoviva. I remain cautious due to financing risks and uncertain commercial viability, despite AP-SA02's clinical promise and FDA support. Looking for more investing ideas like this one? Get them exclusively at Haggerston BioHealth. Learn More » James O'Neil/DigitalVision via Getty Images Investment Overview Armata Pharmaceuticals, Inc. ( ARMP ) stock began trading on the New York Stock Exchange in May 2019 as a result of a merger between C3J Therapeutics and AmpliPhi Biosciences Corporation. At the More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of th
Show less
Read more
Impact Snapshot
Event Time:
ARMP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARMP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARMP alerts
High impacting Armata Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARMP
News
- Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate UpdatePR Newswire
- Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics Landscape [Yahoo! Finance]Yahoo! Finance
- H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod [Yahoo! Finance]Yahoo! Finance
- Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02PR Newswire
- Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus [Yahoo! Finance]Yahoo! Finance
ARMP
Earnings
- 11/12/25 - Miss
ARMP
Sec Filings
- 3/19/26 - Form 8-K
- 3/17/26 - Form 4
- 3/17/26 - Form 4
- ARMP's page on the SEC website